Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer

Smith, 2012, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, Lancet, 379, 39, 10.1016/S0140-6736(11)61226-9 Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N. Engl. J. Med., 378, 1408, 10.1056/NEJMoa1715546 Fizazi, 2019, Darolutamide in nonmetastatic, castration-resistant prostate cancer, N. Engl. J. Med., 380, 1235, 10.1056/NEJMoa1815671 Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N. Engl. J. Med., 378, 2465, 10.1056/NEJMoa1800536 Sternberg, 2020, Final overall survival (OS) from PROSPER: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), J. Clin. Oncol., 38, 10.1200/JCO.2020.38.15_suppl.5515 Fendler, 2019, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer, Clin. Cancer Res., 25, 7448, 10.1158/1078-0432.CCR-19-1050 Small, 2020, Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), J. Clin. Oncol., 38, 10.1200/JCO.2020.38.15_suppl.5516 Fizazi, 2020, Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC), J. Clin. Oncol., 38, 10.1200/JCO.2020.38.15_suppl.5514